No Data
Yongan Pharmaceutical: First Quarter Report 2025
Qianjiang Yongan Pharmaceutical (002365.SZ) turned from a profit to a loss of 4.3672 million yuan in the first quarter.
Gelonghui, on April 28, announced that Qianjiang Yongan Pharmaceutical (002365.SZ) released its first quarter report for 2025. During the reporting period, the company achieved revenue of 0.171 billion yuan, a year-on-year decrease of 12.96%; a net loss of 4.3672 million yuan, compared to a profit of 28.6801 million yuan in the same period last year, with a basic loss per share of 0.0151 yuan.
The price of Vitamins D3 has surged! The Sector responded with a breakout, and Hunan Er-kang Pharmaceutical hit the 20% limit up.
Institutions: It is expected that the domestic Vitamins share will continue to increase.
Qianjiang Yongan Pharmaceutical (002365.SZ): has not yet conducted online direct sales or authorized sales through cross-border e-commerce platforms.
Glonghui, April 17th, Qianjiang Yongan Pharmaceutical (002365.SZ) stated on the interactive platform that the sales model for its product taurine combines sales through agents and direct sales to end customers. Currently, it has not conducted direct online sales or authorized sales through cross-border e-commerce platforms.
Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Shares Climb 26% But Its Business Is Yet to Catch Up
Yongan Pharmaceutical: 2024 Annual Report Summary
Benign Growth For Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) Underpins Stock's 27% Plummet
